Novartis
Novartis AG, a leading global healthcare company headquartered in Switzerland (CH), has established itself as a pioneer in the pharmaceutical industry since its founding in 1996. With a strong presence in key operational regions including North America, Europe, and Asia, Novartis focuses on innovative medicines, generics, and eye care products. The company is renowned for its commitment to research and development, producing unique therapies in areas such as oncology, cardiology, and immunology. Notable achievements include the development of groundbreaking treatments that have transformed patient care. As a top player in the pharmaceutical market, Novartis continues to drive advancements in healthcare, making significant contributions to global health and well-being.
DitchCarbon Score
How does Novartis's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Novartis's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Novartis's reported carbon emissions
In 2023, Novartis reported total carbon emissions of approximately 4,868,900,000 kg CO2e, with emissions distributed across various scopes: 251,100,000 kg CO2e (Scope 1), 44,100,000 kg CO2e (Scope 2), and 4,573,700,000 kg CO2e (Scope 3). This represents a significant reduction from 2020, when total emissions were about 7,982,600,000 kg CO2e. Novartis has set ambitious climate commitments, aiming for carbon neutrality in its own operations (Scope 1 and 2) by 2025 and across its entire supply chain (Scope 1, 2, and 3) by 2030. The company has committed to a 35% reduction in absolute emissions across its value chain by 2030, using 2016 as the baseline year. Furthermore, Novartis aims to achieve net-zero emissions by 2040. The company’s reduction targets include a 100% reduction in Scope 1 and 2 emissions by 2025 and a 50% reduction across all scopes by 2030, both from a 2016 baseline. In the long term, Novartis plans to maintain a minimum of 90% absolute reductions in Scope 1 and 2 emissions from 2030 through 2040, alongside a 90% reduction in Scope 3 emissions by 2040. These initiatives align with Novartis's commitment to sustainability and its participation in the Science Based Targets initiative, reinforcing its role as a leader in the pharmaceutical sector's response to climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2011 | 2012 | 2013 | 2014 | 2016 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 583,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 922,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Novartis is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
